R&D Pipeline
FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), chemotherapy induced anemia (CIA), metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.
Preclinical
Phase 1
Phase 2
Phase 3
Chemotherapy-Induced Anemia
ROXADUSTAT (HIF-PHI)
Metastatic Pancreatic Cancer
PAMREVLUMAB
(ANTI-CTGF ANTIBODY)
Locally Advanced Pancreatic Cancer
FG-3246 (FOR46)
(CD46-TARGETING ADC)
Metastatic Castration-Resistant
Prostate Cancer (mCRPC)
FG-3165
(ANTI-GAL-9 ANTIBODY)
Solid Tumors
FG-3175
(ANTI-CCR8 ANTIBODY)
Solid Tumors
Sponsored by Pancreatic Cancer Action Network
WHOLLY-OWNED
PARTNERED
IN LICENSED
Pamrevlumab
Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.
FG-3246
FG-3246 is a potential first-in-class fully human antibody-drug conjugate (ADC) targeting CD46 being developed for metastatic castration-resistant prostate cancer and with the potential for additional trials targeting other CD46 expressing cancers.
Roxadustat
Roxadustat, the first globally launched oral HIF-PH inhibitor, promotes erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin
